Sangwon Lee, Yeon Ho Choi, Hak Min Kim, Min Ah Hong, Phillip Park, In Hae Kwak, Ye Ji Kang, Kui Son Choi, Hyun-Joo Kong, Hyosung Cha, Hyun-Jin Kim, Kwang Sun Ryu, Young Sang Jeon, Hwanhee Kim, Jip Min Jung, Jeong-Soo Im, Heejung Chae
Cancer Res Treat. 2025;57(1):19-27. Published online July 15, 2024
The common data model (CDM) has found widespread application in healthcare studies, but its utilization in cancer research has been limited. This article describes the development and implementation strategy for Cancer Clinical Library Databases (CCLDs), which are standardized cancer-specific databases established under the Korea-Clinical Data Utilization Network for Research Excellence (K-CURE) project by the Korean Ministry of Health and Welfare. Fifteen leading hospitals and fourteen academic associations in Korea are engaged in constructing CCLDs for 10 primary cancer types. For each cancer type-specific CCLD, cancer data experts determine key clinical data items essential for cancer research, standardize these items across cancer types, and create a standardized schema. Comprehensive clinical records covering diagnosis, treatment, and outcomes, with annual updates, are collected for each cancer patient in the target population, and quality control is based on six-sigma standards. To protect patient privacy, CCLDs follow stringent data security guidelines by pseudonymizing personal identification information and operating within a closed analysis environment. Researchers can apply for access to CCLD data through the K-CURE portal, which is subject to Institutional Review Board and Data Review Board approval. The CCLD is considered a pioneering standardized cancer-specific database, significantly representing Korea’s cancer data. It is expected to overcome limitations of previous CDMs and provide a valuable resource for multicenter cancer research in Korea.
Citations
Citations to this article as recorded by
Glucose tolerance and mortality across 24 cancer types and stages: A K‐CURE Nationwide registry study Kyung‐Hun Sung, Jin Yu, Seyoon Kim, Mee Kyoung Kim, Yong‐Moon Mark Park, Kyungdo Han, Seung‐Hwan Lee Diabetes, Obesity and Metabolism.2026; 28(3): 2051. CrossRef
Nationwide Survival Impact of Bevacizumab Under National Reimbursement for Advanced Cervical Cancer in South Korea Junhwan Kim, Jieun Jang, Krishnansu S. Tewari, Kyung Su Kim, Hyun-Cheol Kang, Sokbom Kang Cancers.2026; 18(2): 346. CrossRef
A Practical Approach to Assessing the Completeness of Electronic Health Records for Medical Research: Data Quality Study Minsik Lim, Doyeon An, Nayeong Son, Woongsang Sunwoo, Suehyun Lee JMIR Medical Informatics.2026; 14: e68935. CrossRef
Impact of Health Behaviors on Cardiovascular Risk in Thyroid Cancer Survivors according to Metastasis: A Nationwide Cohort Study Jeongmin Lee, Jaekyung Lee, Joonseon Park, Kwangsoon Kim, Ja Seong Bae, Kyung-Do Han, Dong-Jun Lim Endocrinology and Metabolism.2026;[Epub] CrossRef
Statin use and survival outcomes in colorectal cancer patients with hepatic steatosis evaluated by fatty liver index: a nationwide cohort study So Hee Lee, Min Ho An, Min-Gyu Kim, Hanki Kim, Soon Sang Park Precision and Future Medicine.2026; 10(2): 63. CrossRef
Disparities in the Diagnosis and Treatment of Endometrial Cancer Among People with Disabilities Joon-Young Hong, Kyungdo Han, Hea Lim Choi, Dong Wook Shin, Yoo-Young Lee International Journal of Gynecological Cancer.2026; 36(9): 104851. CrossRef
Target trial emulation of survival outcomes for clinically localized prostate cancer treatments Min Ho An, Chungsoo Kim, Kyungchan Min, Kyu-Ho Yi, Rae Woong Park, Minji Jung Discover Oncology.2026;[Epub] CrossRef
Exploring PIXE Applications in Oncology: A Comprehensive Review G. J. Naga Raju International Journal of Advanced Research in Science, Communication and Technology.2025; : 261. CrossRef
Disparities in the Diagnosis and Treatment of Breast Cancer Among People With Disabilities Hea Lim Choi, Jin-Hyung Jung, Hwa-Young Lee, Kyungdo Han, Dong Wook Shin JAMA Network Open.2025; 8(11): e2543559. CrossRef
Kidney Failure–Related Mortality in Patients with Cancer: Insights from the Cancer Public Library Database in South Korea Chang Seong Kim, Sang Heon Suh, Hong Sang Choi, Eun Hui Bae, Seong Kwon Ma, Jin Hyung Jung, Bongseong Kim, Kyung-Do Han, Soo Wan Kim Cancer Research and Treatment.2025;[Epub] CrossRef
Predictive Mortality and Gastric Cancer Risk Using Clinical and Socio-Economic Data: A Nationwide Multicenter Cohort Study Seong Uk Kang, Seung-Joo Nam, Oh Beom Kwon, Inhyeok Yim, Tae-Hoon Kim, Na Young Yeo, Myoung Nam Lim, Woo Jin Kim, Sang Won Park Cancers.2024; 17(1): 30. CrossRef
In Hye Song, Young-Ae Kim, Sun-Hee Heo, Won Seon Bang, Hye Seon Park, Yeon ho Choi, Heejae Lee, Jeong-Han Seo, Youngjin Cho, Sung Wook Jung, Hee Jeong Kim, Sei Hyun Ahn, Hee Jin Lee, Gyungyub Gong
Cancer Res Treat. 2022;54(4):1111-1120. Published online December 21, 2021
Purpose
The expression of major histocompatibility complex class I (MHC I) has previously been reported to be negatively associated with estrogen receptor (ER) expression. Furthermore, MHC I expression, level of tumor-infiltrating lymphocytes (TILs), and expression of interferon (IFN) mediator MxA are positively associated with one another in human breast cancers. This study aimed to investigate the mechanisms of association of MHC I with ER and IFN signaling.
Materials and Methods
The human leukocyte antigen (HLA)-ABC protein expression was analyzed in breast cancer cell lines. The expressions of HLA-A and MxA mRNAs were analyzed in MCF-7 cells in Gene Expression Omnibus (GEO) data. ER and HLA-ABC expressions, Ki-67 labeling index and TIL levels in tumor tissue were also analyzed in ER+/ human epidermal growth factor receptor 2 (HER2)- breast cancer patients who randomly received either neoadjuvant chemotherapy or estrogen modulator treatment followed by resection.
Results
HLA-ABC protein expression was decreased after β-estradiol treatment or hESR-GFP transfection and increased after fulvestrant or IFN-γ treatment in cell lines. In GEO data, HLA-A and MxA expression was increased after ESR1 shRNA transfection. In patients, ER Allred score was significantly lower and the HLA-ABC expression, TIL levels, and Ki-67 were significantly higher in the estrogen modulator treated group than the chemotherapy treated group.
Conclusion
MHC I expression and TIL levels might be affected by ER pathway modulation and IFN treatment. Further studies elucidating the mechanism of MHC I regulation could suggest a way to boost TIL influx in cancer in a clinical setting.
Citations
Citations to this article as recorded by
The Immunoregulatory Roles of ERα in Breast Cancer: Mechanisms, Crosstalk, and Therapeutic Insights Afsoon Dehghani Journal of Cancer Prevention.2026; 31(1): 1. CrossRef
Identifying Safeguards Disabled by Epstein-Barr Virus Infections in Genomes From Patients With Breast Cancer: Chromosomal Bioinformatics Analysis Bernard Friedenson JMIRx Med.2025; 6: e50712. CrossRef
Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancer Julio C Tinoco, Harmony I Saunders, Lauryn Rose Werner, Xiaopeng Sun, Eilidh I Chowanec, Amanda Heard, Prabhakar Chalise, Jeffery M Vahrenkamp, Andrea E Wilson, Cong-Xiao Liu, Gangjun Lei, Junping Wei, Hugo Cros, Hisham Mohammed, Melissa Troester, Charles Journal for ImmunoTherapy of Cancer.2025; 13(3): e010179. CrossRef
Neoadjuvant Chemotherapy Efficacy in Breast Cancer: Insights from Magnetic Resonance Imaging Compilation (MAGIC) Honghong Wu, Zebo Huang, Jie Wang Academic Radiology.2025; 32(8): 4369. CrossRef
Prenatal Bisphenol B Exposure Induces Adult Male Offspring Reproductive Dysfunction via ERα Inhibition-Triggered MHC I-Mediated Testicular Immunological Responses Nannan Chen, Xiaotian Li, Shenrui Zhou, Xin Peng, Senlin Xue, Yuetong Liu, Tingwang Jiang, Wei Yan Toxics.2025; 13(6): 423. CrossRef
The untapped potential of radiation and immunotherapy for hormone receptor-positive breast cancer Matthew Fenton, Miki Yoneyama, Erik Wennerberg, Tom Lund, Andrew Tutt, Alan Melcher, Sandra Demaria, Navita Somaiah npj Breast Cancer.2025;[Epub] CrossRef
Dendrimer-Mediated Delivery Enhances Therapeutic Efficacy in Triple-Negative Breast Cancer Anunay James Pulukuri, Anubhav Dhull, Aqib Iqbal Dar, Anu Rani, Rishi Sharma, Clifford E. Berkman, Anjali Sharma Biomacromolecules.2025; 26(9): 5979. CrossRef
Neoadjuvant Immunotherapy in Hormone Receptor-Positive Breast Cancer: From Tumor Microenvironment Reprogramming to Combination Therapy Strategies Zimei Tang, Tao Huang, Tinglin Yang International Journal of Molecular Sciences.2025; 26(23): 11596. CrossRef
Toxic Epidermal Necrolysis and Steven–Johnson Syndrome During the Postpartum Period: A Literature Review with a Rare Case Presentation Natalia Katarzyna Mazur-Ejankowska, Maciej Ejankowski, Magdalena Emilia Grzybowska, Jakub Żółkiewicz, Ewa Gostkowska, Wioletta Barańska-Rybak, Dariusz Grzegorz Wydra Journal of Clinical Medicine.2025; 15(1): 17. CrossRef
Estrogen receptor regulation of the immune microenvironment in breast cancer Conor McGuinness, Kara L. Britt The Journal of Steroid Biochemistry and Molecular Biology.2024; 240: 106517. CrossRef
Bioinformatic-Experimental Screening Uncovers Multiple Targets for Increase of MHC-I Expression through Activating the Interferon Response in Breast Cancer Xin Li, Zilun Ruan, Shuzhen Yang, Qing Yang, Jinpeng Li, Mingming Hu International Journal of Molecular Sciences.2024; 25(19): 10546. CrossRef
Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity Alexandra Moisand, Mathilde Madéry, Thomas Boyer, Charlotte Domblides, Céline Blaye, Nicolas Larmonier International Journal of Molecular Sciences.2023; 24(20): 15048. CrossRef